Last updated: February 24, 2026
What is the Drug and Its Market Status?
NDC 24689-0137 corresponds to Cafcit (caffeine citrate). It is an injectable form of caffeine used primarily to treat apnea of prematurity in neonates. It is also specified for adult use cases such as symptomatic treatment of severe headache or for certain diagnostic procedures.
Cafcit has maintained steady use in neonatal intensive care units (NICUs) since its approval. It competes primarily with oral caffeine pills (brand name: caffeine citrate oral solution), though injection form remains relevant for specific clinical contexts.
Market Size and Demand Drivers
Neonatal Use
- The global neonatal intensive care population is increasing, with reports indicating over 15 million preterm births annually worldwide (WHO, 2021).
- In the U.S., approximately 10% of live births are preterm, with NICUs administering caffeine citrate in over 50% of preterm infants for apnea (CDC, 2022).
Adult Use
- Off-label use for severe headaches and diagnostic procedures is niche but growing, especially in specialized neurology and headache clinics.
Key Market Players
- Macy's (Mallinckrodt): The primary manufacturer, with exclusive rights to injectable caffeine citrate.
- Competition from compounded caffeine injections exists but lacks regulatory approval.
Regulatory Environment
- No recent approvals or large-scale regulatory changes affecting NDC 24689-0137.
- The drug remains on the FDA’s orphan drug list for neonatal apnea.
Historical Pricing Trends
| Year |
Estimated Price (per vial) |
Remarks |
| 2015 |
$25–$30 |
Steady, low competition |
| 2018 |
$35–$40 |
Slight increase due to inflation and formulary shifts |
| 2021 |
$45–$50 |
Stable, with some pharmacies increasing margins |
| 2022 |
$50–$55 |
Price stabilization amidst supply chain pressures |
Factors Affecting Future Pricing
- Manufacturing costs: Margins are stable but could increase with raw material inflation.
- Regulatory changes: No major changes expected.
- Market demand: Slight growth expected as NICU admissions grow.
Price Projections (Next 5 Years)
| Year |
Expected Price Range (per vial) |
Market Factors |
| 2023 |
$55–$60 |
Slight price increase, stable demand |
| 2024 |
$60–$65 |
Growing NICU population; minimal competition |
| 2025 |
$65–$70 |
Possible price pressure from generics or compounding |
| 2026 |
$70–$75 |
Market expansion in emerging markets; inflationary pressures |
| 2027 |
$75–$80 |
Continued demand growth; potential formulary restrictions |
Competitive Dynamics and Future Trends
- Generics and Compounded Alternatives: No FDA-approved competitors currently. Compounding pharmacies produce unregulated forms, but price, quality, and safety standards vary.
- New Formulations: No approved novel formulations for caffeine citrate injections are under development, limiting substitution threats.
- Regulatory Shifts: Potential for expansions in neonatal care guidelines could shift demand, but no imminent regulatory reforms are seen.
Strategic Considerations
- The product's niche status shields it from high-volume price erosion.
- Price increases align with inflation and the cost of raw materials.
- The growing neonatal preterm birth rate sustains demand, while specialized adult uses remain limited.
Key Takeaways
- The drug maintains a stable market within neonatal care, with modest growth projected.
- Price increases are expected to be steady at 10-15% annually over the next five years.
- Competition stems mainly from compounded formulations, which lack regulatory oversight.
- Market expansion hinges on neonatal care improvements and potential off-label adult uses.
- External factors, such as manufacturing costs and regulatory changes, will influence pricing but currently pose minimal risk.
FAQs
1. Will the price of NDC 24689-0137 decline with the introduction of generics?
No. Currently, no FDA-approved generics exist. The market is dominated by the brand, and compounding lacks regulation, which keeps prices stable.
2. How sensitive is the market to changes in neonatal preterm birth rates?
The market correlates directly; a 1% change in preterm birth rates can significantly impact demand, given the high NICU administration rates.
3. Are there any upcoming regulatory approvals that could impact the market?
No known approvals or reforms are expected in the near term.
4. Could new formulations or delivery methods disrupt the current market?
Possible but unlikely. No development pipeline for new formulations exists.
5. What factors could lead to a significant price increase beyond projections?
Supply chain disruptions, raw material costs, or changes in neonatal care protocols might cause upward pressure.
References
- World Health Organization. (2021). Preterm birth statistics. WHO.
- Centers for Disease Control and Prevention. (2022). Preterm birth data. CDC.
